Introduction
The preservation of cognitive function during aging is becoming an increasingly critical public health problem and emerging as one of the major medical challenges of the 21st century, particularly in countries with rapidly aging populations (1,2). Alzheimer's disease, the most frequent cause of dementia, is an age-related neurodegenerative disease, which is characterized by amyloid-β (Aβ) peptide deposition extracellularly and hyperphosphorylated tau protein accumulation intracellularly as neurofibrillary tangles (3, 4) . Although 1-2% of cases of Alzheimer's disease are derived from pathogenic mutations in amyloid precursor protein (APP) and presenilin 1/2 genes, the majority of cases are sporadic and tend to result from pathogenic interactions between multiple factors, including APP/Aβ aging, genetic variants and apolipoprotein E genotype (5) . Although these previous investigations indicate notable links between certain genes and Alzheimer's disease, the exact mechanism underlying the progression of Alzheimer's disease remains to be fully elucidated.
Genome-wide approaches have reshaped the landscape of medical investigations. One of the key mechanisms by which gene expression is controlled, is examined via a complicated process, termed transcriptional regulation, which is mediated through transcription factors. However, the identification of a class of small non-coding RNAs, termed microRNAs (miRNAs), has augmented the complexity of transcriptional regulation and opened a novel field of medical investigations. miRNAs, which consist of 18-24 nucleotides, frequently bind to the 3'-untranslated region (3'-UTR) of target transcripts and regulate gene expression by degrading the target mRNA or inhibiting its translation. They are associated with several biological processes, including development, apoptosis and Alzheimer's disease  via differentially expressed gene and weighted  gene co-expression network analyses proliferation, and their differential expression has been detected in several disorders, including different types of cancer (6) , stroke (7), diabetes (8) , and neurological (9) , and autoimmune diseases (10, 11 The aim of the present study was to identify key genes and biological processes potentially associated with the progression of Alzheimer's disease, which may aid development of small, bioactive molecules. The present study provides important data and theoretical support for investigations of the physiological and pathological processes of Alzheimer's disease.
Identification of therapeutic targets for

Materials and methods
Microarray dataset. The mRNA expression profile of GSE28146 (13) and the miRNA expression profile of GSE16759 (14) were downloaded from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih. gov/geo/). In GSE28146, eight control samples, and samples of Alzheimer's disease comprising seven incipient, eight moderate and seven severe samples were included. Total RNA was extracted from the formalin-fixed-paraffin-emb edded hippocampus (from the GEO public database), and hybridized in the GPL570 Affymetrix HGU 133 Plus 2 microarray (Affymetrix, Inc., Santa Clara, CA, USA). For GSE16759, the miRNA and mRNA expression were profiled for four control samples and four Alzheimer's disease samples. In the present study, only those miRNA expression profiles detected via the GPL8757 USC/XJZ Human 0.9 K miRNA-940-v1.0 microarray platform (www.chibi. ubc.ca/Gemma/arrays/showArrayDesign.html?id=680) were used in the subsequent analysis.
Microarray data analysis. The raw data were converted into a recognizable format in R software. The Affy (15) package (bioconductor.org/packages/release/bioc/html/affy.html) was used for the background correction and normalization of the data. The differentially expressed mRNAs and miRNAs (DEmiRNAs) between the Alzheimer's disease and control samples were identified using the Limma (16) Screening target genes of DEmiRNAs. The validated target genes of the DEmiRNAs were obtained using the miRWalk database (zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2) based on the combination of miRanda, TargetScan, Pictar and miRbase (17) . In addition, the overlap among target genes, genes in the hub module and the DEGs were identified. The miRNA-mRNA regulation network was constructed based on the overlapped genes and their upstream miRNAs, and visualized using Cytoscape software version 2.6.3 (www. cytoscape.org) (18) .
Results
DEGs and DEmiRNAs.
A total of 17,559 genes and 90 DEGs were obtained in the incipient, moderate and severe Alzheimer's disease samples, respectively, compared with control samples. The numbers of upregulated and downregulated genes are listed in Table I . In addition, 164 DEmiRNAs, which contained 74 downregulated and 90 upregulated DEmiRNAs were identified in the Alzheimer's disease samples.
Hub modules of Alzheimer's disease. Through the WGCNA, the first 5,000 genes with the highest CV between the control samples and Alzheimer's disease samples in the mRNA microarray were divided into five gene modules. The largest of these modules contained 2,200 genes, whereas only 52 genes were included in the smallest module. A total of 787 genes were not included in any of the five modules. The correlation coefficients between every gene module, and the age, sex and stage of Alzheimer's disease were also obtained. The distribution of genes in the five gene modules and the importance of each gene module are shown in Fig. 1A and B, respectively. DEGs, differentially expressed genes.
As shown in Fig. 1B , the blue module, which contained 1,592 genes, was the most significant module (correlation coefficient=-0.46; P=0.01) associated with the stage of Alzheimer's disease. Functional enrichment analysis indicated that the GO terms and KEGG pathways associated with the biological processes or diseases of the nervous system were enriched in the genes of the blue module. The top 10 significant GO terms are shown in Table II. Table III shows the 14 enriched KEGG pathways.
Target genes of DEmiRNAs. In the miRWalk database, 746 non-redundant validated target genes were identified for the 164 DEmiRNAs. Five overlaps were obtained, which were regulated by four miRNAs: hsa-mir-376a-2, hsa-mir-376a-1, hsa-mir-15a and hsa-mir-424. The regulation network between those overlapped genes and their upstream miRNAs is shown in Fig. 2 .
Discussion
In the present study, microarray technology was used to identify the therapeutic targets and the associated biological processes for Alzheimer's disease. Using the combination of differentially expressed analysis and WGCNA, several potential targets, including miR-15a and peptidyl-glycine α-amidating monooxygenase (PAM) were obtained. In addition, several biological process and KEGG pathways, which were closely associated with Alzheimer's disease, were further validated.
Sprouty (Spry) proteins contain a carboxyl-terminal cysteine-rich domain, which is essential for the inhibitory activity on receptor tyrosine kinase signaling proteins, and they require growth factors to stimulate translocation of the protein to membrane ruffles. Over previous years, members of the Spry family have emerged as critical modulators of GO, Gene Ontology; BP, biological process; CC, cellular component. 
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growth factor signaling (19, 20) . Mammalian spry genes are expressed in restricted patterns in several adult tissues and in the embryo during development. They are important in the development of various organs, including the kidney, lung, testis and tooth (21) (22) (23) (24) (25) . At the cellular level, the overexpression of Spry proteins antagonizes proliferation, migration and differentiation in response to serum or growth factors in various cell lines (19, 20) . In addition, Gross et al (26) demonstrated that the overexpression of wild-type Spry2 inhibits neurite formation and expression of neurofilament light chain, whereas the inhibition of Spry2 accelerates sprouting of multiple neurites. These findings suggest that Spry2 is potentially involved in neurological disease. The miR-15a/miR16-1 cluster, located on 13q, is important in regulating cell proliferation, apoptosis and expression in the brain, heart, liver, spleen, lung, kidney, small intestine and testis under physiological conditions (27) . Gao et al (28) found that miR-15a is important in the regulation of neuronal maturation, and further confirmed that the overexpression of miR-15a inhibits dendritic morphogenesis in immature neurons, whereas, a reduction in miR-15a has the opposite effect. Another study provided evidence for a potential causal association between the expression of miR-29a/b-1 and generation of Aβ, with the loss of specific miRNAs contributing to increased levels of β-secretase 1 (BACE1) and Aβ in sporadic Alzheimer's disease. Another three miRNAs were also predicted, which had candidate binding sites within the 3'UTRs of BACE1, including miR-15a (also found in the present study), miR-9 and miR-19b (29) . In the present study, an important subgroup of patients with Alzheimer's disease exhibited increased protein expression of Spry2 in the tissue of the hippocampus, and Spry2 was predicted as an important disease marker for Alzheimer's disease. The present study also used the prediction algorithms, miRanda, Targetscan, Pictar and miRbase, which confirmed that miR-15a had candidate binding sites within the 3'UTRs of Spry2, which indicated miR-15a as a potential major suppressor of the protein expression of Spry2.
The results of the present study also suggested that miRNA expression profiles were altered in Alzheimer's disease. Whether these changes were specific for Alzheimer's disease, or whether they were a cause or a consequence of the disease process, and whether these data may be used for diagnosis, remain to be investigated. Another two miRNAs, miR-376-a1 and miR-376-a2, were identified as significantly altered, which had candidate binding sites within the 3'UTRs of PAM, whereas one candidate miRNA-binding site, miR-424, was found within the 3' UTRs of mitogen-activated In conclusion, the findings of the present study suggested a molecular link between miRNA and gene expression potentially involved in Alzheimer's disease. The functions of these genes in Alzheimer's disease require further validation through the use of molecular biology experiments. The present study revealed potential therapeutic targets and associated biological processes through the use of differentially expressed gene analysis and WGCNA, and these findings may assist in the treatment of Alzheimer's disease.
